OMI™ OncoCare
Your trusted partner in precision oncology,
from advanced tumor profiling to minimal
residual disease monitoring for
personalized therapy.
Discover the OMI™ OncoCare Series
An advanced suite of next-generation sequencing (NGS) tests designed to provide clinicians with actionable insights for personalized cancer care
OMI ™ TumorMap
Advanced tumor profiling that delivers critical insights to guide targeted cancer treatment—maximizing effectiveness while minimizing toxicity.
OMI ™ TumorTarget
Precision genetic testing to assess eligibility for specific cancer therapies, including PARP inhibitors and immuno-oncology (IO) treatments.
OMI ™ MRDTracker
Highly sensitive, non-invasive tests for detecting minimal residual disease (MRD), offering personalized insights into cancer progression, metastasis, and treatment response.
OMI ™ Heredity
Advanced hereditary cancer screening empowers individuals to understand their risk and take control of their health.
From diagnosis to treatment selection and ongoing monitoring, OMI ™ OncoCare is here for you at every step.
Advantages of Oncogenetic Testing
Oncogenetic testing empowers clinicians with critical insights to guide treatment decisions, improving patient outcomes through precision medicine.
Targeted Therapy
Identifies actionable mutations, enabling clinicians to prescribe targeted therapies that improve efficacy and minimize unnecessary treatments.
Better Prognosis
Provides a clearer understanding of tumor behavior, allowing for earlier interventions and optimized treatment strategies.
Reduced Side Effects
Helps avoid ineffective treatments, reducing toxicity and enhancing patient quality of life.
Have any questions?
Our dedicated team is here to support you every step of the way, from test selection to sample collection and results interpretation.
Explore Our Comprehensive Testing Solutions
OMI™ TumorMap
OMI™ MRDTrack
OMI™ TumorTarget
OMI™ Heredity
OMI™ TumorMap
Successful cancer treatment requires personalized care. Unlike traditional approaches, precision oncology uses the genetic profiles of both the tumor and patient to guide treatment decisions. OMI TumorMap provides clinicians with key insights to select the most effective therapies, minimize side effects, and optimize responses, ensuring tailored treatments that maximize outcomes and minimize toxicity.
Focus Panel
*Only with germline control
Deep Panel
TumorMap WES
OMI™ MRDTrack: Minimal Residual Disease (MRD) Monitoring
OMI™ MRDTrack + OMI™ WES
OMI OncoCare MRDTrack is a customized MRD gene test for solid tumors. It first utilizes TumorMap WES to analyze the patient’s tumor tissue and identify mutations. A proprietary algorithm selects 40 personalized molecular tags and integrates 21 key tumor driver genes to design custom MRD probes. These probes enable ultra-high depth (100,000X) blood-based MRD monitoring, detecting ultra-low frequency mutations to track tumor recurrence and secondary primary tumors. MRDTrack provides early recurrence warnings before traditional methods like PET scans, guiding timely clinical decisions and optimal treatment strategies.
Exclusive MRD Probes
Exclusive Panel
Based on WES detection data, 40 sites are precisely selected as patient’s exclusive “molecular tags” using a proprietary bioinformatics algorithm.
Core Panel
21 key driver genes related to tumor occurrence and development, monitoring the occurrence of secondary primary tumors, and providing a basis for targeted therapy decisions.
Targeted Therapy
Chemotherapy Endocrine Therapy
Immunotherapy
Hereditary Tumors
Viral Typing
MRDTrack+ detects cancer recurrence earlier than traditional methods, such as PET scans, in different types of cancers
Nasopharyngeal carcinoma
Breast cancer
Pancreatic cancer
Lung cancer
Colon cancer
MRDTrack + Ultra: Advanced MRD Monitoring for Specialized Cancers
Discover MRDTrack+ Ultra – an advanced suite of MRD monitoring tests specially designed for specific types of cancer.
MRD Track+ Ultra implements 60,000X high-depth sequencing, consistently achieving industry-leading 0.02% MRD detection limit
Lung cancer
Digestive tract tumors
Hepatobiliary and Pancreatic tumors
Genes for MRDTrack+ are selected based on relevant guidelines, expert consensus and literature in combination with several databases, including TCGA (Tha Cancer Genome Atlas Program), COSMIC (Catalogue of Somatic Mutations in Cancer), and in-house databases.
OMI™ TumorTarget
While OMI™ TumorMap offers comprehensive genetic profiling across a broad range of cancer therapies, the OMI™ TumorTarget line specializes in delivering targeted insights for specific treatments, such as PARP inhibitors and immuno-oncology therapies, optimizing precision in advanced cancer care.
PARPredict
ImmuneCompass
OMI™ Heredity
Contact us below for a personalized consultation and discover how OMI™ Heredity can benefit you.
Contact Us
Contact
Subscribe to our newsletter
Quick links
Services
